Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.

Ann Rheum Dis · 2023 · PMC10176410 · PMID 36690388

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

LLDAS attainment increased across the 52-week period, and nominally significant differences in LLDAS attainment among patients who were BICLA responders at week 52 were evident from week 12 onwards ( online supplemental table S2 ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.